Global Cancer Vaccines Market Size, Share, and Trends Analysis Report, By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), By Indication (Cervical Cancer, Prostate Cancer, and Others), and By End User (Pediatrics, and Adults) Forecast Period (2022-2028)

The global cancer vaccines market is anticipated to grow at a significant CAGR of 14.8% during the forecast period (2022-2028). Cancer vaccines, also known as therapeutic vaccinations, are a type of immunotherapy that inhibits tumor development, kills cancer cells, and prevents cancer recurrence. According to the WHO, 13.3 million new cancer cases were registered globally in 2020, up from roughly 18 million cancer cases in 2018. 9.9 million mortalities were reported in 2020. With this expanding burden, cancer prevention is one of the major concerns globally. Cancer vaccines, which are considered biological response modifiers, play an important part in the immune system’s maintenance. The rising number of cancer cases, increased investments and government financing in the creation of cancer vaccines, and technological advancements in cancer vaccines are all factors driving the growth of the market.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance,

• In March 2021, The European Commission awarded eTheRNA, a Belgian immunotherapy business, with $7.9million grant to speed the clinical development of mRNA-based vaccinations for cervical malignancies.
• In November 2020, Moderna Inc. released interim results from the expansion cohort of its ongoing Phase-1 study of its mRNA personalized cancer vaccine (PCV) mRNA-4157 in combination with Merck’s Keytruda, showing that the vaccine candidate is well tolerated at all dose levels and produces responses as measured by tumor shrinkage in HPV (-)Head and Neck Squamous Cell Carcinoma (HNSCC) patients.
• In July 2019, Oxford Vacmedix UK Limited (OVM), a UK-based biopharmaceutical firm, cooperated with CHAIN Biotechnology Ltd and the University of Oxford to produce OVM-100, a recombinant overlapping peptide (ROP) HPV vaccination targeted at cervical cancer. This partnership hadreceived an Innovate UK funding.
• In January 2019, Sanofi S.A. invested $91.4million in BioNTech, a German biotech firm, to develop a messenger RNA cancer vaccine for solid tumor treatment.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Technology
  • By Indication
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape- OSE Immunotherapeutics, GlaxoSmithKline Plc, F Hoffmann-La Roche AG (Genentech), Moderna Inc., and Merck & Co. Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cancer Vaccines Market Report by Segment

By Technology

• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines

By Indication

• Cervical Cancer
• Prostate Cancer
• Others

By End-User

• Pediatrics
• Adults

Global Cancer Vaccines Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa